{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:13:39Z","timestamp":1777490019292,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Ireland","award":["For Statistical Analysis Only, Grant N\/A"],"award-info":[{"award-number":["For Statistical Analysis Only, Grant N\/A"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients diagnosed with New Daily Persistent Headache and Persistent Post-Traumatic Headache belong to a heterogeneous group of primary and secondary headache disorders, with the common clinical feature that these conditions start abruptly, continue unabated, and are refractory to conventional migraine preventive treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This is a real-world, medium-term audit to explore whether erenumab improves quality of life in a pooled group of 82 abrupt-onset, unremitting and treatment refractory patients, where the diagnosis is new daily persistent headache and persistent post-traumatic headache in the majority of cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighty-two patients were treated with erenumab every 28 days over a two to three-year period, beginning in December 2018. These patients were \u201clongstanding chronic\u201d and refractory with a median of eight (IQR 4\u201312) prior failed migraine preventive treatments and median duration of disease of seven (IQR 3\u201311) years. The starting dose of erenumab was 70\u2009mg in 79% of cases and 140\u2009mg in the remaining patients (individuals with a BMI of more than 30). All patients were asked to complete three migraine specific Quality of Life questionnaires or Patient Reported Outcome Measures before starting treatment and typically at 3\u201312 intervals until the end of June 2021 or cessation of treatment. The Patient Reported Outcome Measures included: Headache Impact Test-6, Migraine Associated Disability Assessment test and Migraine-Specific Quality-of-Life Questionnaire. Patients generally only stayed on treatment after 6\u201312 months if there was deemed to be an improvement of at least 30% and there were no significant side effects. The longest treated cases have quality of life data for 30 months after starting erenumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 82 patients, 29 (35%) had improvement in Quality of Life scores, with no significant side effects, and wished to stay on treatment. Fifty-three patients (65%) stopped treatment during the first 6\u201325 months due to lack of efficacy and\/or patient reported side effects ( n\u2009=\u200933 and n\u2009=\u200917, respectively) or a combination of both, pregnancy planning ( n\u2009=\u20092), and lost to follow up ( n\u2009=\u20091).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Significant improvements in Quality of Life scores were recorded by one-third of patients over a period of 11\u201330 months, with a 35% persistence after a median of 26 months of treatment. This contrasts with our recently published, treatment resistant, chronic migraine cohort where the persistence with erenumab treatment was almost 55% after a median time of 25 months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024231182126","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T03:24:35Z","timestamp":1686799475000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the majority of cases"],"prefix":"10.1177","volume":"43","author":[{"given":"Alina","family":"Buture","sequence":"first","affiliation":[{"name":"Dublin Neurological Institute, Department of Neurology, Mater Hospital, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther M.","family":"Tomkins","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beaumont Hospital, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arif","family":"Shukralla","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beaumont Hospital, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Troy","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beaumont Hospital, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Conaty","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beaumont Hospital, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Macken","sequence":"additional","affiliation":[{"name":"Dublin Neurological Institute, Department of Neurology, Mater Hospital, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roisin","family":"Lonergan","sequence":"additional","affiliation":[{"name":"Dublin Neurological Institute, Department of Neurology, Mater Hospital, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Melling","sequence":"additional","affiliation":[{"name":"Dublin Neurological Institute, Department of Neurology, Mater Hospital, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niamh","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beaumont Hospital, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieran","family":"Birrane","sequence":"additional","affiliation":[{"name":"Independent Statistical Consultant, Wilton, Cork, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eamonn","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beaumont Hospital, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3260-5904","authenticated-orcid":false,"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[{"name":"NIHR King\u2019s Clinical Research Facility, King\u2019s College London, UK"},{"name":"Department of Neurology, University of California, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin H.","family":"Ruttledge","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beaumont Hospital, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"bibr1-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-11-94"},{"key":"bibr2-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"bibr3-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1111\/head.14207"},{"key":"bibr4-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1111\/head.14362"},{"key":"bibr5-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1111\/head.12707"},{"key":"bibr6-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01872.x"},{"key":"bibr7-03331024231182126","doi-asserted-by":"publisher","DOI":"10.4103\/0972-2327.100011"},{"key":"bibr8-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.227793"},{"key":"bibr9-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420927119"},{"key":"bibr10-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1080\/02699052.2020.1807052"},{"key":"bibr11-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01136-z"},{"key":"bibr12-03331024231182126","first-page":"97","volume":"61","author":"Spierings ELH","year":"2021","journal-title":"Headache"},{"key":"bibr13-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01536-3"},{"key":"bibr14-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000313"},{"key":"bibr15-03331024231182126","first-page":"433","volume":"42","author":"Rozen TD.","year":"2002","journal-title":"Headache"},{"key":"bibr16-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2020.09.014"},{"key":"bibr17-03331024231182126","first-page":"897","volume":"46","author":"Rozen TD","year":"2006","journal-title":"Headache"},{"key":"bibr18-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2005.03524.x"},{"key":"bibr19-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2008.05.036"},{"key":"bibr20-03331024231182126","doi-asserted-by":"publisher","DOI":"10.1111\/head.14224"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024231182126","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024231182126","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024231182126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:45:55Z","timestamp":1777387555000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024231182126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1177\/03331024231182126"],"URL":"https:\/\/doi.org\/10.1177\/03331024231182126","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"article-number":"03331024231182126"}}